TY - JOUR T1 - Development of multi-drug resistant tuberculosis among patients treated with category II regimen: A lung center of the Philippines experience JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P2690 AU - Sablan Augusto, Jr AU - Joven Gonong AU - Lawrence Raymond AU - Vivian Lofranco Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P2690.abstract N2 - We need to re-evaluate the use of Category II since this contradicts the principle of adding a single drug to a failing regimen.We did a retrospective chart review of patients who received category II from December 2006 until December 2009. The objective was to determined the incidence of MDR-TB among patients who received category II regimen.There were 363 patients who received category II treatment 16 (4.4%) patients had mono-resistance, 14 (3.9%) patients had Polyresistance, 129 (35.5%) were MDR-TB. 152 (41.9%) were culture negative and 52 (14.3%) were culture positive but fully susceptible. Of the 129 patients who developed MDR-TB, 58 (45%) belonged to the Category I failure group, 46 (33.3%) belonged to the Relapse group and 25 (27.5%) belonged to the RAD group.View this table:Incidence of MDR-TBThe incidence of MDR-TB among patients who received category II treatment from was 35.5%. Of these, the highest was among Category I failure at 45%, followed by Relapse 35.6% and RAD at 19.4%.We recommend that patients with category I failure should no longer receive category II treatment. Instead, MDR-TB screening should be done and standardized treatment for MDR-TB should be started. As for RAD, and Relapse, MDR-TB screening should also be done and we need to carefully re-evaluate the use of Category II treatment regimen. ER -